The New York Entrepreneur

FDA expected to decide on Pfizer RSV vaccine for older adults by May 2023

Read Time:7 Second

Pfizer said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post ‘There is a slowdown happening’ – Wells Fargo, BofA CEOs point to cooling consumer amid Fed hikes
Next post : EIA reports a weekly drop in U.S. crude supplies, product stocks rise